BMS's novel immunotherapy ipilimumab could gain US approval this year for melanoma
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's novel immunotherapy ipilimumab could become the first new therapy approved for melanoma in more than a decade in the US after the FDA accepted the BLA for the treatment of previously treated advanced melanoma and also designated the filing a priority review.